nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—CACNA1S—pes—muscle cancer	0.175	0.323	CbGeAlD
Nimodipine—CACNA1F—head—muscle cancer	0.0204	0.0376	CbGeAlD
Nimodipine—CACNA1F—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.0178	0.0732	CbGpPWpGaD
Nimodipine—CACNB4—tendon—muscle cancer	0.0156	0.0289	CbGeAlD
Nimodipine—CACNB4—vagina—muscle cancer	0.0145	0.0268	CbGeAlD
Nimodipine—CACNB4—head—muscle cancer	0.0134	0.0247	CbGeAlD
Nimodipine—CACNA1S—tendon—muscle cancer	0.0134	0.0247	CbGeAlD
Nimodipine—CACNB4—testis—muscle cancer	0.0129	0.0239	CbGeAlD
Nimodipine—CACNB4—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.0126	0.0516	CbGpPWpGaD
Nimodipine—CACNB1—tendon—muscle cancer	0.0125	0.023	CbGeAlD
Nimodipine—CACNB3—tendon—muscle cancer	0.012	0.0221	CbGeAlD
Nimodipine—AHR—smooth muscle tissue—muscle cancer	0.0118	0.0218	CbGeAlD
Nimodipine—CACNB3—vagina—muscle cancer	0.0111	0.0205	CbGeAlD
Nimodipine—CACNB1—head—muscle cancer	0.0107	0.0198	CbGeAlD
Nimodipine—CACNB1—testis—muscle cancer	0.0103	0.0191	CbGeAlD
Nimodipine—CACNB3—head—muscle cancer	0.0103	0.0189	CbGeAlD
Nimodipine—AHR—cardiac atrium—muscle cancer	0.0102	0.0188	CbGeAlD
Nimodipine—CACNB3—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.01	0.0412	CbGpPWpGaD
Nimodipine—CACNB3—testis—muscle cancer	0.00991	0.0183	CbGeAlD
Nimodipine—CACNB1—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.00976	0.0401	CbGpPWpGaD
Nimodipine—CACNB2—cardiac atrium—muscle cancer	0.00923	0.017	CbGeAlD
Nimodipine—AHR—tendon—muscle cancer	0.00887	0.0164	CbGeAlD
Nimodipine—CACNA1C—smooth muscle tissue—muscle cancer	0.00864	0.0159	CbGeAlD
Nimodipine—AHR—bone marrow—muscle cancer	0.00859	0.0159	CbGeAlD
Nimodipine—AHR—vagina—muscle cancer	0.00823	0.0152	CbGeAlD
Nimodipine—CACNA1D—cardiac atrium—muscle cancer	0.00807	0.0149	CbGeAlD
Nimodipine—CACNB2—tendon—muscle cancer	0.00804	0.0149	CbGeAlD
Nimodipine—NR3C2—smooth muscle tissue—muscle cancer	0.00786	0.0145	CbGeAlD
Nimodipine—CYP3A5—Vincristine—muscle cancer	0.00785	0.344	CbGbCtD
Nimodipine—NR3C2—renal system—muscle cancer	0.00757	0.014	CbGeAlD
Nimodipine—CACNB2—vagina—muscle cancer	0.00747	0.0138	CbGeAlD
Nimodipine—CACNA1C—cardiac atrium—muscle cancer	0.00745	0.0137	CbGeAlD
Nimodipine—AHR—testis—muscle cancer	0.00734	0.0136	CbGeAlD
Nimodipine—NR3C2—Preimplantation Embryo—HMGA1—muscle cancer	0.00719	0.0296	CbGpPWpGaD
Nimodipine—CYP3A5—Etoposide—muscle cancer	0.00719	0.315	CbGbCtD
Nimodipine—CACNA1S—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.00715	0.0294	CbGpPWpGaD
Nimodipine—CACNB2—head—muscle cancer	0.0069	0.0127	CbGeAlD
Nimodipine—NR3C2—cardiac atrium—muscle cancer	0.00678	0.0125	CbGeAlD
Nimodipine—CACNB2—testis—muscle cancer	0.00666	0.0123	CbGeAlD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—CALD1—muscle cancer	0.00663	0.0272	CbGpPWpGaD
Nimodipine—Ileus—Vincristine—muscle cancer	0.00662	0.0344	CcSEcCtD
Nimodipine—CACNB2—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.00613	0.0252	CbGpPWpGaD
Nimodipine—CACNA1D—head—muscle cancer	0.00603	0.0111	CbGeAlD
Nimodipine—CACNA1C—vagina—muscle cancer	0.00602	0.0111	CbGeAlD
Nimodipine—CACNB4—Developmental Biology—MYF6—muscle cancer	0.00599	0.0246	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—MYF5—muscle cancer	0.00599	0.0246	CbGpPWpGaD
Nimodipine—NR3C2—tendon—muscle cancer	0.00591	0.0109	CbGeAlD
Nimodipine—CACNA1D—testis—muscle cancer	0.00582	0.0107	CbGeAlD
Nimodipine—CACNA1D—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.00581	0.0239	CbGpPWpGaD
Nimodipine—CACNA1C—head—muscle cancer	0.00556	0.0103	CbGeAlD
Nimodipine—NR3C2—vagina—muscle cancer	0.00548	0.0101	CbGeAlD
Nimodipine—CACNA1C—testis—muscle cancer	0.00537	0.00992	CbGeAlD
Nimodipine—AHR—Adipogenesis—HMGA1—muscle cancer	0.00517	0.0212	CbGpPWpGaD
Nimodipine—CACNA1C—Arrhythmogenic Right Ventricular Cardiomyopathy—DMD—muscle cancer	0.0051	0.021	CbGpPWpGaD
Nimodipine—NR3C2—head—muscle cancer	0.00506	0.00935	CbGeAlD
Nimodipine—NR3C2—testis—muscle cancer	0.00489	0.00903	CbGeAlD
Nimodipine—CACNB3—Developmental Biology—MYF6—muscle cancer	0.00479	0.0197	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MYF5—muscle cancer	0.00479	0.0197	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MYF6—muscle cancer	0.00466	0.0191	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MYF5—muscle cancer	0.00466	0.0191	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.00455	0.0187	CbGpPWpGaD
Nimodipine—Phlebitis—Dactinomycin—muscle cancer	0.00442	0.023	CcSEcCtD
Nimodipine—CYP3A5—renal system—muscle cancer	0.00409	0.00755	CbGeAlD
Nimodipine—CACNB4—Developmental Biology—MYOG—muscle cancer	0.00386	0.0159	CbGpPWpGaD
Nimodipine—Lactic dehydrogenase activity increased—Doxorubicin—muscle cancer	0.00384	0.02	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Etoposide—muscle cancer	0.00379	0.0198	CcSEcCtD
Nimodipine—Deep vein thrombosis—Methotrexate—muscle cancer	0.00373	0.0194	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.00358	0.0147	CbGpPWpGaD
Nimodipine—Liver function test abnormal—Dactinomycin—muscle cancer	0.00351	0.0183	CcSEcCtD
Nimodipine—AHR—Adipogenesis—FOXO1—muscle cancer	0.00343	0.0141	CbGpPWpGaD
Nimodipine—Hyponatraemia—Vincristine—muscle cancer	0.00341	0.0178	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—MYF5—muscle cancer	0.00341	0.014	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MYF6—muscle cancer	0.00341	0.014	CbGpPWpGaD
Nimodipine—Blood lactate dehydrogenase increased—Doxorubicin—muscle cancer	0.00339	0.0176	CcSEcCtD
Nimodipine—Phlebitis—Etoposide—muscle cancer	0.0032	0.0166	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.00317	0.0165	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—MYOG—muscle cancer	0.00308	0.0127	CbGpPWpGaD
Nimodipine—CYP3A4—renal system—muscle cancer	0.00307	0.00567	CbGeAlD
Nimodipine—CYP3A4—Vincristine—muscle cancer	0.00306	0.134	CbGbCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.00304	0.0125	CbGpPWpGaD
Nimodipine—Cardiac failure congestive—Etoposide—muscle cancer	0.00304	0.0158	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—MYOG—muscle cancer	0.003	0.0123	CbGpPWpGaD
Nimodipine—CYP3A5—vagina—muscle cancer	0.00296	0.00547	CbGeAlD
Nimodipine—CACNB2—Developmental Biology—MYF6—muscle cancer	0.00292	0.012	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MYF5—muscle cancer	0.00292	0.012	CbGpPWpGaD
Nimodipine—CYP3A4—Etoposide—muscle cancer	0.0028	0.123	CbGbCtD
Nimodipine—Ileus—Doxorubicin—muscle cancer	0.00278	0.0145	CcSEcCtD
Nimodipine—CACNA1D—Developmental Biology—MYF5—muscle cancer	0.00277	0.0114	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MYF6—muscle cancer	0.00277	0.0114	CbGpPWpGaD
Nimodipine—Hepatitis—Dactinomycin—muscle cancer	0.00263	0.0137	CcSEcCtD
Nimodipine—Depression—Vincristine—muscle cancer	0.00261	0.0136	CcSEcCtD
Nimodipine—CACNA1F—Alzheimers Disease—TP53—muscle cancer	0.00253	0.0104	CbGpPWpGaD
Nimodipine—Cramp muscle—Etoposide—muscle cancer	0.00248	0.0129	CcSEcCtD
Nimodipine—Flushing—Dactinomycin—muscle cancer	0.00244	0.0127	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—MYF5—muscle cancer	0.00243	0.01	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MYF6—muscle cancer	0.00243	0.01	CbGpPWpGaD
Nimodipine—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00243	0.0126	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—MYOD1—muscle cancer	0.00238	0.00979	CbGpPWpGaD
Nimodipine—Sweating increased—Etoposide—muscle cancer	0.00232	0.0121	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—MYOG—muscle cancer	0.0022	0.00903	CbGpPWpGaD
Nimodipine—Cardiac disorder—Vincristine—muscle cancer	0.00218	0.0114	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—MED12—muscle cancer	0.00218	0.00896	CbGpPWpGaD
Nimodipine—Angiopathy—Vincristine—muscle cancer	0.00213	0.0111	CcSEcCtD
Nimodipine—Anaemia—Dactinomycin—muscle cancer	0.00212	0.011	CcSEcCtD
Nimodipine—Jaundice—Etoposide—muscle cancer	0.00207	0.0108	CcSEcCtD
Nimodipine—Hepatobiliary disease—Etoposide—muscle cancer	0.00201	0.0104	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00197	0.0102	CcSEcCtD
Nimodipine—Myalgia—Dactinomycin—muscle cancer	0.00195	0.0102	CcSEcCtD
Nimodipine—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00192	0.0079	CbGpPWpGaD
Nimodipine—CYP3A4—Doxorubicin—muscle cancer	0.00191	0.0838	CbGbCtD
Nimodipine—CACNB3—Developmental Biology—MYOD1—muscle cancer	0.00191	0.00783	CbGpPWpGaD
Nimodipine—Anaemia—Vincristine—muscle cancer	0.00189	0.00985	CcSEcCtD
Nimodipine—CACNB2—Developmental Biology—MYOG—muscle cancer	0.00188	0.00774	CbGpPWpGaD
Nimodipine—Oedema—Dactinomycin—muscle cancer	0.00187	0.00974	CcSEcCtD
Nimodipine—Fluid retention—Doxorubicin—muscle cancer	0.00187	0.00973	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—MYOD1—muscle cancer	0.00185	0.00762	CbGpPWpGaD
Nimodipine—Thrombocytopenia—Dactinomycin—muscle cancer	0.00183	0.00953	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00182	0.00749	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MYOG—muscle cancer	0.00178	0.00733	CbGpPWpGaD
Nimodipine—Flushing—Etoposide—muscle cancer	0.00177	0.00921	CcSEcCtD
Nimodipine—Cardiac disorder—Etoposide—muscle cancer	0.00177	0.00921	CcSEcCtD
Nimodipine—Hypertension—Vincristine—muscle cancer	0.00177	0.0092	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—MED12—muscle cancer	0.00174	0.00716	CbGpPWpGaD
Nimodipine—Myalgia—Vincristine—muscle cancer	0.00174	0.00907	CcSEcCtD
Nimodipine—Angiopathy—Etoposide—muscle cancer	0.00173	0.009	CcSEcCtD
Nimodipine—Immune system disorder—Etoposide—muscle cancer	0.00172	0.00896	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.0017	0.00887	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—MED12—muscle cancer	0.0017	0.00697	CbGpPWpGaD
Nimodipine—Oedema—Vincristine—muscle cancer	0.00167	0.0087	CcSEcCtD
Nimodipine—NR3C2—Generic Transcription Pathway—MED12—muscle cancer	0.00166	0.00683	CbGpPWpGaD
Nimodipine—Phlebitis—Doxorubicin—muscle cancer	0.00166	0.00863	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.00164	0.00855	CcSEcCtD
Nimodipine—Nervous system disorder—Vincristine—muscle cancer	0.00164	0.00853	CcSEcCtD
Nimodipine—Thrombocytopenia—Vincristine—muscle cancer	0.00164	0.00852	CcSEcCtD
Nimodipine—Hyperhidrosis—Vincristine—muscle cancer	0.00161	0.00841	CcSEcCtD
Nimodipine—Muscle spasms—Etoposide—muscle cancer	0.00159	0.0083	CcSEcCtD
Nimodipine—Cardiac failure congestive—Doxorubicin—muscle cancer	0.00157	0.0082	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—MYOG—muscle cancer	0.00157	0.00644	CbGpPWpGaD
Nimodipine—Hypotension—Vincristine—muscle cancer	0.00156	0.00813	CcSEcCtD
Nimodipine—Anaemia—Etoposide—muscle cancer	0.00153	0.00798	CcSEcCtD
Nimodipine—Liver function test abnormal—Methotrexate—muscle cancer	0.00152	0.00793	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00152	0.00793	CcSEcCtD
Nimodipine—CACNB4—Transmission across Chemical Synapses—MDM2—muscle cancer	0.00148	0.00608	CbGpPWpGaD
Nimodipine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00144	0.00751	CcSEcCtD
Nimodipine—Hyponatraemia—Doxorubicin—muscle cancer	0.00143	0.00747	CcSEcCtD
Nimodipine—Hypertension—Etoposide—muscle cancer	0.00143	0.00745	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00143	0.00744	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.00138	0.00569	CbGpPWpGaD
Nimodipine—Hypersensitivity—Dactinomycin—muscle cancer	0.00138	0.00717	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—MYOD1—muscle cancer	0.00136	0.00558	CbGpPWpGaD
Nimodipine—Thrombocytopenia—Etoposide—muscle cancer	0.00132	0.0069	CcSEcCtD
Nimodipine—Tachycardia—Etoposide—muscle cancer	0.00132	0.00688	CcSEcCtD
Nimodipine—Liver function test abnormal—Doxorubicin—muscle cancer	0.00132	0.00687	CcSEcCtD
Nimodipine—Hyperhidrosis—Etoposide—muscle cancer	0.00131	0.00681	CcSEcCtD
Nimodipine—Diarrhoea—Dactinomycin—muscle cancer	0.00128	0.00666	CcSEcCtD
Nimodipine—Depression—Methotrexate—muscle cancer	0.00127	0.0066	CcSEcCtD
Nimodipine—Hypotension—Etoposide—muscle cancer	0.00126	0.00658	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00126	0.00656	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—MED12—muscle cancer	0.00124	0.0051	CbGpPWpGaD
Nimodipine—Hypersensitivity—Vincristine—muscle cancer	0.00123	0.00641	CcSEcCtD
Nimodipine—CACNB3—Metabolism—FH—muscle cancer	0.00123	0.00504	CbGpPWpGaD
Nimodipine—Dyspnoea—Etoposide—muscle cancer	0.00121	0.00628	CcSEcCtD
Nimodipine—Hepatobiliary disease—Methotrexate—muscle cancer	0.0012	0.00626	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—FOXO1—muscle cancer	0.0012	0.00492	CbGpPWpGaD
Nimodipine—Vomiting—Dactinomycin—muscle cancer	0.00119	0.00619	CcSEcCtD
Nimodipine—CACNB3—Transmission across Chemical Synapses—MDM2—muscle cancer	0.00118	0.00486	CbGpPWpGaD
Nimodipine—Rash—Dactinomycin—muscle cancer	0.00118	0.00614	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00117	0.00608	CcSEcCtD
Nimodipine—CACNB2—Developmental Biology—MYOD1—muscle cancer	0.00116	0.00478	CbGpPWpGaD
Nimodipine—CACNB1—Transmission across Chemical Synapses—MDM2—muscle cancer	0.00115	0.00473	CbGpPWpGaD
Nimodipine—Diarrhoea—Vincristine—muscle cancer	0.00114	0.00595	CcSEcCtD
Nimodipine—Hepatitis—Methotrexate—muscle cancer	0.00114	0.00594	CcSEcCtD
Nimodipine—CACNB4—Neuronal System—MDM2—muscle cancer	0.00113	0.00466	CbGpPWpGaD
Nimodipine—Nausea—Dactinomycin—muscle cancer	0.00111	0.00578	CcSEcCtD
Nimodipine—Dizziness—Vincristine—muscle cancer	0.0011	0.00575	CcSEcCtD
Nimodipine—CACNA1D—Developmental Biology—MYOD1—muscle cancer	0.0011	0.00453	CbGpPWpGaD
Nimodipine—Jaundice—Doxorubicin—muscle cancer	0.00107	0.00559	CcSEcCtD
Nimodipine—CACNB2—Developmental Biology—MED12—muscle cancer	0.00106	0.00437	CbGpPWpGaD
Nimodipine—Vomiting—Vincristine—muscle cancer	0.00106	0.00553	CcSEcCtD
Nimodipine—Cardiac disorder—Methotrexate—muscle cancer	0.00106	0.00551	CcSEcCtD
Nimodipine—Rash—Vincristine—muscle cancer	0.00105	0.00548	CcSEcCtD
Nimodipine—Dermatitis—Vincristine—muscle cancer	0.00105	0.00548	CcSEcCtD
Nimodipine—Headache—Vincristine—muscle cancer	0.00105	0.00545	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.00105	0.0043	CbGpPWpGaD
Nimodipine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00104	0.00542	CcSEcCtD
Nimodipine—Angiopathy—Methotrexate—muscle cancer	0.00104	0.00539	CcSEcCtD
Nimodipine—Immune system disorder—Methotrexate—muscle cancer	0.00103	0.00537	CcSEcCtD
Nimodipine—CACNA1S—Alzheimers Disease—TP53—muscle cancer	0.00102	0.00418	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MED12—muscle cancer	0.00101	0.00414	CbGpPWpGaD
Nimodipine—Bradycardia—Doxorubicin—muscle cancer	0.00101	0.00524	CcSEcCtD
Nimodipine—Hypersensitivity—Etoposide—muscle cancer	0.000997	0.00519	CcSEcCtD
Nimodipine—Nausea—Vincristine—muscle cancer	0.000992	0.00517	CcSEcCtD
Nimodipine—Hepatitis—Doxorubicin—muscle cancer	0.000988	0.00514	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—MYOD1—muscle cancer	0.000969	0.00398	CbGpPWpGaD
Nimodipine—Pruritus—Etoposide—muscle cancer	0.000957	0.00499	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—FOXO1—muscle cancer	0.000957	0.00393	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—FOXO1—muscle cancer	0.000931	0.00382	CbGpPWpGaD
Nimodipine—Diarrhoea—Etoposide—muscle cancer	0.000926	0.00482	CcSEcCtD
Nimodipine—Anaemia—Methotrexate—muscle cancer	0.000918	0.00478	CcSEcCtD
Nimodipine—Flushing—Doxorubicin—muscle cancer	0.000917	0.00477	CcSEcCtD
Nimodipine—Cardiac disorder—Doxorubicin—muscle cancer	0.000917	0.00477	CcSEcCtD
Nimodipine—CACNB3—Neuronal System—MDM2—muscle cancer	0.000907	0.00372	CbGpPWpGaD
Nimodipine—Angiopathy—Doxorubicin—muscle cancer	0.000896	0.00467	CcSEcCtD
Nimodipine—Dizziness—Etoposide—muscle cancer	0.000895	0.00466	CcSEcCtD
Nimodipine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000894	0.00367	CbGpPWpGaD
Nimodipine—Immune system disorder—Doxorubicin—muscle cancer	0.000892	0.00465	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—MED12—muscle cancer	0.000886	0.00364	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—MDM2—muscle cancer	0.000882	0.00362	CbGpPWpGaD
Nimodipine—Vomiting—Etoposide—muscle cancer	0.00086	0.00448	CcSEcCtD
Nimodipine—Rash—Etoposide—muscle cancer	0.000853	0.00444	CcSEcCtD
Nimodipine—Dermatitis—Etoposide—muscle cancer	0.000852	0.00444	CcSEcCtD
Nimodipine—Headache—Etoposide—muscle cancer	0.000848	0.00441	CcSEcCtD
Nimodipine—Myalgia—Methotrexate—muscle cancer	0.000846	0.0044	CcSEcCtD
Nimodipine—AHR—Circadian rythm related genes—TP53—muscle cancer	0.000832	0.00342	CbGpPWpGaD
Nimodipine—Muscle spasms—Doxorubicin—muscle cancer	0.000827	0.00431	CcSEcCtD
Nimodipine—CACNA1D—Alzheimers Disease—TP53—muscle cancer	0.000826	0.00339	CbGpPWpGaD
Nimodipine—Nausea—Etoposide—muscle cancer	0.000804	0.00419	CcSEcCtD
Nimodipine—NR3C2—Gene Expression—MED12—muscle cancer	0.0008	0.00329	CbGpPWpGaD
Nimodipine—Nervous system disorder—Methotrexate—muscle cancer	0.000795	0.00414	CcSEcCtD
Nimodipine—Anaemia—Doxorubicin—muscle cancer	0.000795	0.00414	CcSEcCtD
Nimodipine—Thrombocytopenia—Methotrexate—muscle cancer	0.000794	0.00413	CcSEcCtD
Nimodipine—Hyperhidrosis—Methotrexate—muscle cancer	0.000784	0.00408	CcSEcCtD
Nimodipine—CACNB4—Axon guidance—VEGFA—muscle cancer	0.000764	0.00314	CbGpPWpGaD
Nimodipine—Palpitations—Doxorubicin—muscle cancer	0.00076	0.00396	CcSEcCtD
Nimodipine—Hypotension—Methotrexate—muscle cancer	0.000757	0.00394	CcSEcCtD
Nimodipine—CACNB2—Metabolism—FH—muscle cancer	0.000749	0.00308	CbGpPWpGaD
Nimodipine—Hypertension—Doxorubicin—muscle cancer	0.000743	0.00387	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000739	0.00385	CcSEcCtD
Nimodipine—Myalgia—Doxorubicin—muscle cancer	0.000732	0.00381	CcSEcCtD
Nimodipine—CACNA1C—Alzheimers Disease—TP53—muscle cancer	0.000726	0.00298	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—MDM2—muscle cancer	0.000723	0.00297	CbGpPWpGaD
Nimodipine—Dyspnoea—Methotrexate—muscle cancer	0.000723	0.00376	CcSEcCtD
Nimodipine—CACNA1D—Metabolism—FH—muscle cancer	0.00071	0.00292	CbGpPWpGaD
Nimodipine—Oedema—Doxorubicin—muscle cancer	0.000702	0.00365	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.0007	0.00364	CcSEcCtD
Nimodipine—CACNB3—Metabolism—MED12—muscle cancer	0.000693	0.00285	CbGpPWpGaD
Nimodipine—Nervous system disorder—Doxorubicin—muscle cancer	0.000688	0.00358	CcSEcCtD
Nimodipine—Thrombocytopenia—Doxorubicin—muscle cancer	0.000687	0.00358	CcSEcCtD
Nimodipine—Tachycardia—Doxorubicin—muscle cancer	0.000685	0.00357	CcSEcCtD
Nimodipine—CACNA1S—Developmental Biology—FOXO1—muscle cancer	0.000682	0.0028	CbGpPWpGaD
Nimodipine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000679	0.00353	CcSEcCtD
Nimodipine—Hypotension—Doxorubicin—muscle cancer	0.000656	0.00342	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000639	0.00333	CcSEcCtD
Nimodipine—CACNB3—Metabolism—ENO2—muscle cancer	0.000632	0.0026	CbGpPWpGaD
Nimodipine—Dyspnoea—Doxorubicin—muscle cancer	0.000626	0.00326	CcSEcCtD
Nimodipine—CACNA1C—Metabolism—FH—muscle cancer	0.000624	0.00256	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—VEGFA—muscle cancer	0.000611	0.00251	CbGpPWpGaD
Nimodipine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000606	0.00316	CcSEcCtD
Nimodipine—Hypersensitivity—Methotrexate—muscle cancer	0.000597	0.00311	CcSEcCtD
Nimodipine—CACNB1—Axon guidance—VEGFA—muscle cancer	0.000594	0.00244	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—FOXO1—muscle cancer	0.000584	0.0024	CbGpPWpGaD
Nimodipine—Pruritus—Methotrexate—muscle cancer	0.000573	0.00299	CcSEcCtD
Nimodipine—Diarrhoea—Methotrexate—muscle cancer	0.000555	0.00289	CcSEcCtD
Nimodipine—CACNB2—Neuronal System—MDM2—muscle cancer	0.000554	0.00228	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—FOXO1—muscle cancer	0.000553	0.00227	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—VEGFA—muscle cancer	0.000545	0.00224	CbGpPWpGaD
Nimodipine—Dizziness—Methotrexate—muscle cancer	0.000536	0.00279	CcSEcCtD
Nimodipine—Hypersensitivity—Doxorubicin—muscle cancer	0.000517	0.00269	CcSEcCtD
Nimodipine—Vomiting—Methotrexate—muscle cancer	0.000515	0.00268	CcSEcCtD
Nimodipine—Rash—Methotrexate—muscle cancer	0.000511	0.00266	CcSEcCtD
Nimodipine—Dermatitis—Methotrexate—muscle cancer	0.000511	0.00266	CcSEcCtD
Nimodipine—Headache—Methotrexate—muscle cancer	0.000508	0.00264	CcSEcCtD
Nimodipine—Pruritus—Doxorubicin—muscle cancer	0.000497	0.00259	CcSEcCtD
Nimodipine—CACNA1C—Developmental Biology—FOXO1—muscle cancer	0.000486	0.002	CbGpPWpGaD
Nimodipine—Nausea—Methotrexate—muscle cancer	0.000481	0.00251	CcSEcCtD
Nimodipine—Diarrhoea—Doxorubicin—muscle cancer	0.00048	0.0025	CcSEcCtD
Nimodipine—Dizziness—Doxorubicin—muscle cancer	0.000464	0.00242	CcSEcCtD
Nimodipine—Vomiting—Doxorubicin—muscle cancer	0.000446	0.00232	CcSEcCtD
Nimodipine—Rash—Doxorubicin—muscle cancer	0.000443	0.0023	CcSEcCtD
Nimodipine—Dermatitis—Doxorubicin—muscle cancer	0.000442	0.0023	CcSEcCtD
Nimodipine—Headache—Doxorubicin—muscle cancer	0.00044	0.00229	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—VEGFA—muscle cancer	0.000436	0.00179	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—VEGFA—muscle cancer	0.000435	0.00179	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—VEGFA—muscle cancer	0.000424	0.00174	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—MED12—muscle cancer	0.000423	0.00174	CbGpPWpGaD
Nimodipine—Nausea—Doxorubicin—muscle cancer	0.000417	0.00217	CcSEcCtD
Nimodipine—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000401	0.00165	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—MED12—muscle cancer	0.000401	0.00165	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—ENO2—muscle cancer	0.000386	0.00159	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—VEGFA—muscle cancer	0.000373	0.00153	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—ENO2—muscle cancer	0.000366	0.0015	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—VEGFA—muscle cancer	0.000353	0.00145	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—MED12—muscle cancer	0.000352	0.00145	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—ENO2—muscle cancer	0.000321	0.00132	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—VEGFA—muscle cancer	0.000311	0.00128	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—VEGFA—muscle cancer	0.000311	0.00128	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—FH—muscle cancer	0.000276	0.00113	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—VEGFA—muscle cancer	0.000266	0.00109	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—VEGFA—muscle cancer	0.000252	0.00104	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—VEGFA—muscle cancer	0.000222	0.00091	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PTGS2—muscle cancer	0.00022	0.000904	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—MED12—muscle cancer	0.000156	0.000641	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—ENO2—muscle cancer	0.000142	0.000584	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PTGS2—muscle cancer	0.000134	0.000552	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—FH—muscle cancer	0.000128	0.000527	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PTGS2—muscle cancer	0.000127	0.000523	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PTGS2—muscle cancer	0.000112	0.00046	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—MED12—muscle cancer	7.25e-05	0.000298	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—ENO2—muscle cancer	6.61e-05	0.000272	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PTGS2—muscle cancer	4.95e-05	0.000203	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PTGS2—muscle cancer	2.3e-05	9.46e-05	CbGpPWpGaD
